- Home
- INLX vs ANL Comparison
INLX vs ANL Comparison
Compare INLX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INLX
- ANL
- Stock Information
- Founded
- INLX 1996
- ANL 2004
- Country
- INLX United States
- ANL Cayman Islands
- Employees
- INLX N/A
- ANL N/A
- Industry
- INLX EDP Services
- ANL
- Sector
- INLX Technology
- ANL
- Exchange
- INLX Nasdaq
- ANL Nasdaq
- Market Cap
- INLX 53.5M
- ANL 56.0M
- IPO Year
- INLX N/A
- ANL 2023
- Fundamental
- Price
- INLX $12.05
- ANL $1.45
- Analyst Decision
- INLX
- ANL Hold
- Analyst Count
- INLX 0
- ANL 1
- Target Price
- INLX N/A
- ANL N/A
- AVG Volume (30 Days)
- INLX 1.9K
- ANL 6.9K
- Earning Date
- INLX 08-12-2025
- ANL 08-12-2025
- Dividend Yield
- INLX N/A
- ANL N/A
- EPS Growth
- INLX N/A
- ANL N/A
- EPS
- INLX N/A
- ANL N/A
- Revenue
- INLX $17,758,634.00
- ANL N/A
- Revenue This Year
- INLX $2.47
- ANL N/A
- Revenue Next Year
- INLX $7.72
- ANL N/A
- P/E Ratio
- INLX N/A
- ANL N/A
- Revenue Growth
- INLX 3.21
- ANL N/A
- 52 Week Low
- INLX $7.75
- ANL $1.10
- 52 Week High
- INLX $16.50
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- INLX 40.87
- ANL 44.72
- Support Level
- INLX $12.95
- ANL $1.48
- Resistance Level
- INLX $13.66
- ANL $1.55
- Average True Range (ATR)
- INLX 0.46
- ANL 0.04
- MACD
- INLX -0.18
- ANL -0.00
- Stochastic Oscillator
- INLX 0.00
- ANL 25.00
About INLX Intellinetics Inc.
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.